Conservative Management of HSIL in Patients With Future Pregnancy Aspiration

Related Clinical Trial
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring Educational Video’s Impact on Knowledge Regarding Cervical Cancer Screening Primary Cervical Cancer Screening by Self-sampling HPV Test Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2) Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022 Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests Diagnostic Cervical Conization for Persistent Infection or Integration of HPV DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment Cervical Cancer Screening Strategies DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening The Organ Transplant Recipient HPV and Skin Cancer Study Effect of HPV Integration on Prognosis of Young Women With CIN2 in China Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV Prevention and Screening Towards Elimination of Cervical Cancer HPV-based Screening Among Women 23-29 Years of Age Clinical Evaluation of Detection of High Risk HPV in Urine The Vaginal Microecology and Innate Immunity After Focused Ultrasound Ablation Treatment for CIN Large Loop Excision of the Transformation Zone (LLETZ) With vs Without IntraOperative Application of Lugol’s Iodine Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia Optimization of Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico Low-cost Imaging Technology for Global Prevention of Cervical Cancer Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia Depth of Necrosis in Normal Cervical Epithelium After 85% Trichloroacetic Acid (TCA) Application Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples Conservative Management of HSIL in Patients With Future Pregnancy Aspiration Clinical Validation of Cervical Cancer Screening Methods Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400) Virtual Reality: Influence on Satisfaction, Pain, and Anxiety in Patients Undergoing Colposcopy Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) Pembrolizumab for the Treatment of High-Grade Vulvar, Vaginal, or Cervical Intraepithelial Neoplasia Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial DNA Methylation Testing for the Screening of Uterine Cervical Lesion Immunohistochemical Staining of p16 for the Screening of Cervical Cancer CASUS: Validation for Detection of Precursor Lesions CASUS: Improved and Quality Assured Collection of First-void Urine Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) Lugol’s Solution in Addition to Acetic Acid During Colposcopy A Phase I Study of E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors Costa Rican Natural History Study of HPV and Cervical Neoplasia Measurement of Digital Colposcopy for Fluorescence Spectroscopy of TNC Using a Second Device Effect of Salpingectomy During Conservative Hysterectomy Feasibility of Delphi Screener for Cervical Cytology Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection Gene Therapy Follow up for Subjects Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) – Types in HIV-positive Men Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY Minimally Invasive Benign Hysterectomy HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 – Brazil) Diagnostic Imaging Aid for Management of Cervical Lesions Cervical Cancer Early Endpoints and Determinants Triage Strategies in Cervical Cancer Prevention Genotypification and Predisposing Factors in Human Papilloma Virus Infection Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity Chinese Cancer Prevention Study(CHICAPS) The Development of a “Mother/Child, Screen, Treat and Vaccinate Program” in Manchay and Iquitos, Peru HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings A Trial for Patients With Advanced/Recurrent Cervical Cancer HPV Genotyping by DR. HPV Genotyping in Vitro Diagnostic Device (IVD) Kit in Exfoliated Cells of the Uterine Cervix Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer Self-sampling for Non-attenders to Cervical Cancer Screening HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix Human Papillomavirus Epidemiology in Nigeria Impact of HPV Vaccine On The Prevalence Of HPV In Norway Deciphering Mechanisms Underlying Cancer Immunogenicity Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests Spectroscopic Evaluation of Cervical Neoplasia Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3) Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals’ (GSK Bio) HPV-16/18 Vaccine Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women DNA Methylation Biomarkers for Cervical Cancer Screening Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix Can Text Reminders Improve Uptake of Cervical Screening? Comparing Two Techniques of Haemostasis After Cervical Conization A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening FASTER-Tlalpan Study HPV Integration Testing for Human Papillomavirus-Positive Women Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine Cervical Cytology – Do SMS Reminders Increase Participation in the Cervical Screening Programme? Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection Effectiveness of Cervical Screening in HPV Vaccinated Women Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples Effect of Fee on Attendance in Cervical Cancer Screening Cervix Cytological Screening – Comparison of Tampon Self-Test and the Routine Smear. Study of the Diagnostic Efficacy of “Real Time” Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix LLETZ Under General Versus Local Anesthesia Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs) Trial on Safety and Pharmacokinetics of Intravaginal Curcumin IMproved PRactice Outcomes and Value Excellence in Colposcopy Visual Inspection With Acetic Acid Compared to Lugol’s Iodine in HIV-infected Women Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine Clinical Evaluation of Polarized Light Assisted Colposcopy Indirect Comparison Topotecan Cervical Carcinoma Meta-analysis of Efficacy of Topotecan Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals’ HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study TMTP1-ICG Mapping in Colposcopy-directed Biopsy Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1 Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model Endocervical Evaluation With the Curette Versus Cytobrush for the Diagnosis of Dysplasia of the Uterine Cervix Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation The HPV Self-test as a Test of Cure in Madagascar REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) A Trial of Two Electrosurgical Conizations: Histopathological Analysis of Excision Margins Cold Knife Conization With and Without Lateral Hemostatic Sutures DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2 A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake Improving Cervical Cancer Screening Among HIV-Infected Women in India REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Compass – Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia chemQbiosciences:Manual Liquid Based Cytology A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Music Listening to Reduce Pain and Anxiety During LEEP A Comparison of Immediate Treatment of CIN1 With Cryotherapy and 12 Month Cytology Follow up in HIV Seropositive Women Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia Cervical And Self-Sample In Screening Study Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Factors Associated With Residual Disease In The Central Cone Trial to Evaluate Single- and Double- Freeze Cryotherapy in the Prevention of Cervical Neoplasia Colposcopy Versus HPV Testing to Identify Persistent Cervical Precancers Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Effectiveness of HPV Vaccine in Thai Adult Women Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia Artesunate Vaginal Inserts for the Treatment of CIN2/3 A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) Trial23 – A Method Study on Cervical Screening in Women Offered HPV-vaccination as Girls An Innovative Treatment for Cervical Pre Cancer A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix LLETZ Under Direct Colposcopic Vision The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation LLETZ With Videocolposcopy Versus LLETZ With Binocular Colposcopy Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol Colposcopy and Dynamic Spectral Imaging (DSI) Imiquimod Treatment of High-grade CIN Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Video Colposcopy in Women With Dysplasia Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Imiquimod Treatment of CIN Lesions HPV Integration Testing for Cervical Cancer Screening Hemostatic Procedure After Biopsy of the Cervix HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 Fischer Cone Biopsy Excisor Versus Loop Excision Procedure for Conization A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) Coherence Imaging of the Cervical Epithelium With Scanning a/LCI Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia See and Treat in an Outpatient Setting in Women Above 45 Years With Cervical Dysplasia Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women Smoking Cessation in Women With Gynecological Conditions Recurrence in High-grade Lesions After Conization Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence Management of Cervical Intraepithelial Neoplasia Grade 2 Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) An Innovative Treatment for Cervical Precancer (UH3) Evaluating Materials to Educate Patients About Cervical Dysplasia A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia Performance, Safety, and Efficacy of a New Cryotherapy Device for Cervical Dysplasia [Part II] Music and Colposcopy in Women With Cervical Dysplasia. Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 Focal Ablation of Cervical Precancer Digital Imaging Aid for Assessment of Cervical Dysplasia Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2) Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia Can Alternative Treatment Have an Impact on Cervical Dysplasia? Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure

Brief Title

Conservative Management of HSIL in Patients With Future Pregnancy Aspiration

Official Title

Conservative Management of Patients Diagnosed With High-grade Squamous Intraepithelial Lesions (H-SIL) Who Have Pregnancy Intentions: a Prospective Observational Study

Brief Summary

      Conservative management of high-grade squamous intraepithelial lesions (HSILs) seems safe and
      justified in young women (<30 years), but evidence is insufficient on whether it is also
      advisable for older women.

      This study will be conducted to analyze spontaneous HSIL regression rates in women of
      reproductive age and establish whether conservative HSIL management could be safely
      recommended to women of childbearing potential, irrespective of age.

      This is a single-center prospective observational study that will include consecutive women
      of reproductive age, referred to a tertiary hospital due to HSIL between March 2021 and
      December 2025, who prefer conservative management rather than immediate cervical conization.

      All patients will be followed-up regularly with colposcopy, cytology, human papillomavirus
      (HPV) testing and biopsies. In case their lesions progress or HSIL persists after 24 months
      of follow-up, conization will be indicated. Rates of spontaneous regression or resolution, as
      well as progression rates, will be assessed. Furthermore, the association between potential
      predictive factors and HSIL resolution will be analyzed.

Detailed Description

      In most developed countries, two main strategies are currently used for cervical cancer
      prevention: primary prevention with human papillomavirus (HPV) vaccination, and systematic
      screening with periodic cytology or HPV testing. Nevertheless, a significant number of women
      are still diagnosed with high-grade squamous intraepithelial lesions (HSIL), with higher
      prevalence rates among younger women (0.6% between ages 20 and 29; 0.2% between 40 and 49).
      Since the average age at first pregnancy in Catalonia is 32.2 years, many patients have not
      yet fulfilled their reproductive intentions when they are diagnosed with HSIL.

      Most HSIL cases are treated surgically with cervical conization, although previous studies
      have indicated that this may increase the incidence of preterm labor in future pregnancies.
      Therefore, many women diagnosed with HSIL will undergo treatment that may affect their future
      reproductive life.

      In patients diagnosed with HSIL, conservative management with periodic evaluations would be
      an efficient alternative to surgery, with the expectation of spontaneous resolution. Recent
      studies have shown that 40-88% of HSIL lesions can regress spontaneously within two years,
      especially in women under 25. Furthermore, a meta-analysis of 36 studies involving 3160
      patients concluded that active surveillance of patients diagnosed with cervical
      intraepitelial neoplasia (CIN) grade 2, rather than immediate surgical treatment, is
      justified, especially in young women (<30 years). Recent clinical guidelines include active
      surveillance as a valid option for management of HSIL in fertile women, with no age

      Although the biological behavior of CIN2 without surgical treatment has been described in
      numerous studies, few included lesions classified as CIN3. Since the latest anatomical and
      pathological classification of the World Health Organization does not make any distinction
      between CIN2 and CIN3, classifying both as HSIL, treatment guidelines should be uniform for
      all HSILs, without discriminating between CIN2 or CIN3.

      Furthermore, although several studies have demonstrated the safety of conservative management
      for HSIL in women younger than 25-30 years, there is insufficient information in women aged
      30-40 years. Therefore, further evidence is still needed on the rate of spontaneous
      regression of HSIL (both CIN2 and CIN3) and on the safety of active surveillance, so that
      conservative management may be considered in all women who wish to become pregnant in the

      The main goal of this study will be to analyze whether spontaneous HSIL (CIN2 and CIN3)
      regression rates in women of reproductive age are high enough to support conservative
      management without age restrictions. We aim to describe the rates of spontaneous HSIL
      regression, HSIL persistence and HSIL progression in women under conservative management.
      Furthermore, we aim to describe predictive factors associated with HSIL regression rates. If
      this study confirms the safety of conservative management of HSIL, it could be possible to
      reduce the number of cervical conizations in these patients.

      Aim This will be a prospective observational cohort study performed at a Lower Genital Tract
      (LGT) unit of a tertiary hospital (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)
      affiliated with a cytology-based cervical cancer screening program. In this center, all
      colposcopic examinations are performed by two senior colposcopists, accredited by the Spanish
      Association for Cervical Pathology and Colposcopy (AEPCC). Pathology samples are analyzed by
      specialist technicians from the Pathology department of the same hospital and reviewed by
      expert pathologists. HPV tests are performed for all patients in the same laboratory using
      Genómica's Clart Human Papillomavirus 4.

      Patients All women referred to our LGT unit with biopsy-confirmed histological diagnosis of
      HSIL (CIN2 or CIN3) are assessed with colposcopy and counseled by expert gynecologists.
      Patients considered suitable for conservative management (instead of immediate surgical
      treatment with cervical conization) are routinely informed of the potential risks and
      benefits of both cervical conization and active surveillance of HSIL. Then, a shared decision
      is made for either surveillance or immediate conization. To be considered suitable for
      conservative management, women must: be of reproductive age; have transformation zone type 1
      or 2 (fully visible squamous-columnar union) at colposcopy, with a fully visible lesion and
      no atypical glandular cells (AGC) at cytology; and commit to attend follow-up visits at
      regular intervals.

      This study will start in March 2021 and will be concluded in December 2027. Consecutive women
      of reproductive age referred to our center from March 2021 to December 2025 with a diagnosis
      of HSIL that are considered suitable for conservative management and freely chose active
      surveillance will be invited to participate in this study. Patients will be followed-up for a
      minimum of 2 years.

      Eligibility criteria include positive high-risk (hr) HPV cytology, reproductive age and a
      wish to pursue pregnancy in the future. Women who are pregnant at diagnosis, immunosuppressed
      or diagnosed with carcinoma in situ of the cervix or cervical cancer will be excluded.

      This study was approved by the institution's ethics committee. Written informed consent will
      be obtained from all patients. All follow-up visits and clinical tests will be performed
      according to standard patient care and no tests or visits will be conditioned to
      participation in the study, nor will any additional treatment be given to patients enrolled.
      Verbal informed consent to continue conservative treatment will be reviewed at each follow-up
      visit. At any time during follow-up, patients can choose to have conization.

      Follow-up visits will be performed every 4 months, including colposcopy and cytology at each
      visit. Biopsies will not performed routinely, but on a case-by-case basis according to
      changes observed in colposcopy. The follow-up interval will be extended to 6 months if
      cytology and biopsies indicated low-grade squamous intraepithelial lesion (LSIL) or atypical
      squamous cells of undetermined significance (ASCUS) and this result is consistent with
      colposcopy. HPV will be determined every 8 12 months. This follow-up protocol will be
      continued until resolution of HSIL. Patients will be referred back to primary care when no
      HSIL is detected by cytology, colposcopy or biopsies and if HPV is negative at two
      consecutive visits.

      Conservative management will be discontinued and conization will be indicated if HSIL
      persists after 24 months of follow-up, if the patient no longer meet criteria for
      surveillance, or under the patient's request.

      All information will be retrieved from electronic patient files. Demographic data, smoking
      status, parity, use of contraceptives and colposcopy will be recorded. Information from
      pathology reports of cytology, biopsies and conization specimens will be collected, and time
      to HSIL resolution, regression or progression will be recorded.

      Patients will be classified into two groups according to the outcome of active surveillance:
      spontaneous HSIL regression or conization (women who had cervical conization for any reason
      during follow-up). Patients with spontaneous HSIL regression will be further classified into
      3 subgroups: total resolution (no colposcopic lesion, normal pathology by biopsy and
      cytology, and negative HPV for the HPV type initially detected); partial resolution
      (regression of colposcopic lesion, negative cytology and biopsies, but persistence of the
      initial hrHPV detected); and lesion regression (HSIL no longer detected, but persistent LSIL
      in either cytology, histology or colposcopy). Patients who eventually have conization will be
      further classified according to indication criteria: failure to meet criteria for
      conservative management or persistence of HSIL after 24 months of follow-up.

      Data analysis Patient characteristics will be described according to whether their lesions
      regress spontaneously or conization is indicated throughout the follow-up period. Numbers and
      percentages will be provided for categorical variables, whereas means and standard deviations
      will be used for quantitative variables.

      The association between potential predictive variables and HSIL resolution will be analyzed
      with chi-square tests (or Fisher's exact test when appropriate) for categorical variables and
      t-tests for quantitative variables. Variables assessed will include: age and ethnicity,
      smoking status, number of sexual partners within the previous 6 months, HPV type, alternative
      therapies, HPV vaccination.

      The characteristics of patients who have conization will be summarized, comparing patients
      referred to surgery because they failed to meet surveillance criteria to those referred to
      surgery due to persistence of HSIL at end of follow-up. The statistical analysis will be
      performed with SPSS version 26.0 (SPSS Inc., Chicago, IL, USA). Differences between groups
      were considered statistically significant at p < 0.05.

Study Type


Primary Outcome

HSIL regression


Cervical Intraepithelial Neoplasia


Conservative management with regular follow-up

Study Arms / Comparison Groups

 Spontaneous HSIL regression
Description:  Patients that have spontaneous regression of HSIL throughout follow-up. Patients in this group will be further classified into 3 subgroups: total resolution (no colposcopic lesion, normal pathology by biopsy and cytology, and negative HPV for the HPV type initially detected); partial resolution (regression of colposcopic lesion, negative cytology and biopsies, but persistence of the initial hrHPV detected); and lesion regression (HSIL no longer detected, but persistent LSIL in either cytology, histology or colposcopy).


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Diagnostic Test

Estimated Enrollment


Start Date

March 3, 2021

Completion Date

December 31, 2027

Primary Completion Date

December 31, 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Reproductive age and aspirations of future pregnancies

          -  Acceptance of conservative management

          -  Commitment to attend scheduled follow-up visits

          -  Colposcopy with transformation zone (ZT) type 1 or 2 (fully visible squamous-columnar
             union) with lesion with grade 2 changes visible in its entirety. No endocervical

          -  Colposcopy with grade 2 changes that are not extensive: <50% of the cervical surface

        Exclusion Criteria:

          -  Pregnancy at first visit or during follow-up.

          -  Immunosuppression (either iatrogenic or due to human immunodeficiency virus (HIV))

          -  Suspected or diagnosed Atypical Glandular Cells (ACG), In Situ Adenocarcinoma (AIS) or
             Cervical Cancer (CC)




N/A - N/A

Accepts Healthy Volunteers



Cristina Vanrell Barbat, MD, +34604311873, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Study Sponsor

Cristina Vanrell Barbat, MD, Study Director, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Verification Date

March 2021